

U.S. Vaccines: Table 1
(For Combination Vaccines, See Table 2)

Vaccine	Trade Name	Abbreviation	Manufacturer	Route	Doses in Routine Series	Approved Ages	Comments
Adenovirus	Adenovirus Type 4 & Type 7		Barr Labs Inc.	Oral (2 Tablets)	1	17-50 years	Live: Approved for military populations
Anthrax	BioThrax®	AVA	Emergent BioSolutions	IM	3	18-65 years	Inactivated, Adj.
Cholera	Vaxchora®		PaxVax	Oral (Liquid)	1	18-64 years	Live Attenuated
DTaP	Daptacel®	DTaP	sanofi	IM	5	6 weeks-6 years	Inactivated, Adj.
	Infanrix®	DTaP	GlaxoSmithKline	IM	5	6 weeks-6 years	Inactivated, Adj.
DT	Generic	DT	sanofi	IM	5	6 weeks-6 years	Inactivated, Adj.: Use when pertussis is contraindicated
<i>Haemophilus influenzae</i> type b (Hib)	ActHIB®	Hib (PRP-T)	sanofi	IM	4	2 months-5 years	Inactivated, Adj. (Tetanus toxoid conjugate)
	Hiberix®	Hib (PRP-T)	GlaxoSmithKline	IM	4	6 weeks-4 years	Inactivated, Adj. (Tetanus toxoid conjugate)
	PedvaxHIB®	Hib (PRP-OMP)	Merck	IM	3	2-71 months	Inactivated, Adj. (Meningococcal conjugate)
Hepatitis A	Havrix®	HepA	GlaxoSmithKline	IM	2	Pediatric: 12 months-18 years Adult: ≥19 years	Inactivated, Adj.
	Vaqta®	HepA	Merck	IM	2	Pediatric: 12 months-18 years Adult: ≥19 years	Inactivated, Adj.
Hepatitis B	Engerix-B®	HepB	GlaxoSmithKline	IM	3	Pediatric: Birth-19 years Adult: ≥20 years	Recombinant, Adj.
	Recombivax HB®	HepB	Merck	IM	3	Pediatric: Birth-19 years Adult: ≥20 years	Recombinant, Adj.
	Heplisav-B®	HepB	Dynavax Technologies	IM	2	≥18 years	Recombinant, Adj.
Herpes Zoster (Shingles)	Zostavax®	ZVL	Merck	SC	1	≥50 years	Live Attenuated ACIP recommends ≥60 years
	Shingrix®	RZV	GlaxoSmithKline	IM	2	≥50 years	Recombinant, Adj.

Vaccine	Trade Name	Abbreviation	Manufacturer	Route	Doses in Routine Series	Approved Ages	Comments
Human Papillomavirus (HPV)	Gardasil® 9	9vHPV	Merck	IM	2 or 3	9-45 years	Recombinant, Adj. ACIP recommends 9-26 years
Influenza	Afluria®	IIV3 IIV4	Seqirus	IM	1 or 2	≥5 years	Inactivated
	Fluad®	IIV3	Seqirus	IM	1	≥65 years	Inactivated, Adj.
	Fluarix®	IIV4	GlaxoSmithKline	IM	1 or 2	≥6 months	Inactivated
	Flublok®	RIV4	sanofi	IM	1	≥18 years	Recombinant, Egg-Free
	Flucelvax®	ccIIV4	Seqirus	IM	1 or 2	≥4 years	Cell-Culture
	FluLaval®	IIV4	GlaxoSmithKline	IM	1 or 2	≥6 months	Inactivated
	FluMist®	LAIV4	Medimmune	Intranasal	1 or 2	2-49 years	Live Attenuated
	Fluzone® Fluzone® High-Dose	IIV3 IIV4 IIV3	sanofi sanofi	IM IM	1 or 2 1	≥6 months ≥65 years	Inactivated Inactivated
Japanese encephalitis	Ixiaro®	JE	Valneva	IM	2	≥2 months	Inactivated, Adj.
Measles, Mumps, Rubella	M-M-R® II	MMR	Merck	SC	2	≥12 months	Live Attenuated
Meningococcal	Menactra®	MCV4 MenACWY-D	sanofi	IM	2	9 months-55 years	Inactivated (Diphtheria toxoid conjugate)
	Menveo®	MCV4 MenACWY-CRM	GlaxoSmithKline	IM	2	2 months-55 years	Inactivated (CRM ₁₉₇ conjugate)
	Trumenba®	MenB-FHbp	Pfizer	IM	2 or 3	10-25 years	Recombinant, Adj.
	Bexsero®	MenB-4C	GlaxoSmithKline	IM	2	10-25 years	Recombinant, Adj.
Pneumococcal	Pneumovax® 23	PPSV23	Merck	IM or SC	1	≥2 years	Inactivated Polysaccharide
	Prevnar 13®	PCV13	Pfizer	IM	4	≥6 months	Inactivated, Adj. (CRM ₁₉₇ conjugate)
Polio	Ipol®	IPV	sanofi	IM or SC	4	≥6 months	Inactivated
Rabies	Imovax® Rabies		sanofi	IM	3 (pre-exposure) 5 (post-exposure)	All ages	Inactivated
	RabAvert®		GlaxoSmithKline	IM	3 (pre-exposure) 5 (post-exposure)	All ages	Inactivated
Rotavirus	RotaTeq®	RV5	Merck	Oral (Liquid)	3	6-32 weeks	Live, Pentavalent
	Rotarix®	RV1	GlaxoSmithKline	Oral (Liquid)	2	6-24 weeks	Live, Monovalent

Vaccine	Trade Name	Abbreviation	Manufacturer	Route	Doses in Routine Series	Approved Ages	Comments
Tetanus, (reduced) Diphtheria	Tenivac®	Td	sanofi	IM	1 (Every 10 years)	≥7 years	Inactivated, Adj.
	TDVAX™	Td	Massachusetts Biological Labs	IM	1 (Every 10 years)	≥7 years	Inactivated, Adj.
Tetanus, (reduced) Diphtheria, (reduced) Pertussis	Boostrix®	Tdap	GlaxoSmithKline	IM	1	≥10 years	Inactivated, Adj.
	Adacel®	Tdap	sanofi	IM	1	10-64 years	Inactivated, Adj.
Typhoid	Typhim Vi®		sanofi	IM	1	≥2 years	Inactivated, Polysaccharide
	Vivotif®		PaxVax	Oral (Capsules)	4	≥6 years	Live Attenuated
Varicella	Varivax®	VAR	Merck	SC	2	≥12 months	Live Attenuated
Vaccinia (Smallpox)	ACAM2000®		sanofi	Percutaneous	1	All ages	Live Attenuated
Yellow Fever	YF-Vax®	YF	sanofi	SC	1	≥9 months	Live Attenuated

**U.S. Vaccines: Table 2
(Combination Vaccines)**

Vaccine	Trade Name	Abbreviation	Manufacturer	Route	Doses in Routine Series	Approved Ages	Comments
DTaP, Polio	Kinrix®	DTaP-IPV	GlaxoSmithKline	IM	1	4-6 years	Inactivated, Adj.: Approved as 5 th DTaP and 4 th IPV.
	Quadracel™	DTaP-IPV	sanofi	IM	1	4-6 years	Inactivated, Adj.: Approved as 5 th DTaP and 4 th IPV.
DTaP, hepatitis B, Polio	Pediarix®	DTaP-HepB-IPV	GlaxoSmithKline	IM	3	6 weeks-6 years	Inactivated, Adj.: Approved for 2, 4, 6 month doses.
DTaP, Polio, <i>Haemophilus influenzae</i> type b	Pentacel®	DTaP-IPV/Hib	sanofi	IM	4	6 weeks-4 years	Inactivated, Adj.: Approved for 2, 4, 6, 15-18 month doses.
Hepatitis A, Hepatitis B	Twinrix®	HepA-HepB	GlaxoSmithKline	IM	3	≥18 years	Inactivated/Recombinant, Adj. Pediatric HepA + Adult HepB
Measles, Mumps, Rubella, Varicella	ProQuad®	MMRV	Merck	SC	2	12 months-12 years	Live Attenuated

Notes

- The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the *Morbidity and Mortality Weekly Report (MMWR)*, the editor of *Epidemiology and Prevention of Vaccine-Preventable Diseases* (the *Pink Book*), ACIP members, and liaison organizations to the ACIP.

These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the *MMWR*, the *Pink Book*, and the American Academy of Pediatrics *Red Book*, and in the U.S. immunization schedules for children, adolescents, and adults.

In descriptions of combination vaccines, a hyphen (-) indicates products in which the active components are supplied in their final (combined) form by the manufacturer; a slash (/) indicates products in which active components must be mixed by the user.

- “Doses in a Routine Series” (Column 6) reflects doses administered to a healthy patient at the recommended ages. It doesn’t necessarily reflect schedules for patients with health conditions or other high-risk factors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of doses *for that product*, and not necessarily the total number of doses in a complete series for the components. (For example, Kinrix or Quadracel may be used for only 1 dose of multi-dose DTaP and IPV series.)
- “Adj.” in the “Comments” column indicates that the vaccine contains an adjuvant.
- A hyphen in an age range means “through” (i.e., “6 weeks–6 years” means 6 weeks through 6 years [to the 7th birthday]).